Tenet Healthcare Clocks 40% Decline In Q4 Profit, Issues Q1 Guidance Below Consensus

Tenet Healthcare Corp's THC Q4 FY21 adjusted EPS came in at $2.70, down from $4.72 a year ago.

  • Net operating revenue hit $4.86 billion, down 1.2% Y/Y, missing the consensus of $5.00 billion.
  • Adjusted EBITDA was $1.02 billion versus $1.28 million posted in the last year's quarter.
  • Hospital segment revenues were $3.91 billion, a decline of 3.8% primarily due to the sale of Miami-area hospitals, partially offset by higher patient acuity and improved pricing yield.
  • Same-hospital net patient service revenues increased 1.7% Y/Y; same-hospital net patient service revenue per adjusted admission improved 1.7%.
  • The Ambulatory segment revenues of $742 million increased 14.3%, primarily related to higher volumes, patient acuity, new service line growth, and additional revenues associated with the SurgCenter Development portfolio acquisition.
  • Surgical business same-facility system-wide net operating revenues increased 7.7%, with cases up 4.4% and revenue per case up 3.2%.
  • The company plans to retire the $700 million of its 7.50% senior secured notes due in 2025 using available cash on hand. 
  • The company held $2.36 billion in cash and cash equivalents.
  • Outlook: Tenet forecasts FY22 sales of $19.5 billion - $19.9 billion, below the consensus of $20.28 billion.
  • The company expects adjusted EPS of $5.86 - $7.05, compared to the consensus of $6.62.
  • For Q1 FY22, Tenet expects adjusted EPS of $0.92- $1.15, compared to the consensus of $1.43, with sales guidance of $4.6 billion - $4.8 billion, versus the consensus of $4.98 billion.
  • Price Action: THC shares closed lower by 3.90% at $70.00 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!